Single-cell focus Samplix offers a droplet-based single-cell analysis platform (Xdrop) with double-emulsion droplets enabling high-resolution, single-cell readouts. sales opportunities exist in immunotherapy research, engineered cell therapy, protein engineering and synthetic biology workflows where cell-level granularity and rapid screening are valuable.

High-throughput potential Xdrop Sort enables microfluidics-based high-throughput screening and sorting, appealing to labs seeking faster decision cycles and reduced screening times due to rapid buildup of detectable secreted substances within droplets.

Service accessibility Samplix has launched a comprehensive service program to grant laboratories access to Xdrop technology, presenting a channel for B2B partnerships, contract research, and enablement of customers who lack in-house capabilities.

Market positioning With revenue in the low to mid single digits and a lean team, Samplix competes with larger biotech players by offering specialized single-cell and CRISPR validation services, presenting up-sell opportunities for advanced validation workflows and integration with existing sequencing or profiling platforms.

Expansion synergy Recent and ongoing funding-backed development initiatives aim to broaden functional characterization of single cells, creating cross-sell potential for instrument sales, consumables, and data analysis services to customers in immunotherapy, gene editing and synthetic biology sectors.